Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Item No. 24739

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.
Angiotensin II (5-8) is an endogenous C-terminal fragment of the peptide vasoconstrictor angiotensin II (Item No. 17150).1 It inhibits renin (Item No. 10006217) release from rat kidney slices at a concentration of 50 μM and relaxes rat aorta pre-contracted with phenylephrine (Item Nos. 17205 | 18619; EC50 = 0.28 μM).2,1 In vivo, microinjection of angiotensin II (5-8) into the ventrolateral periaqueductal gray (vlPAG) of rats increases mean arterial pressure (MAP) and decreases heart rate (HR) by approximately 2.7- and 3-fold less, respectively, than angiotensin II.1 It increases the latency to withdrawal in a tail-flick test and the mechanical withdrawal threshold in an incision allodynia test in rats when administered at a dose of 0.2 nmol into the vlPAG. Angiotensin II (5-8) (0.4 nmol, vlPAG microinjection) reduces the number of entries and time spent in the open arms of the elevated plus maze and increases the mean startle amplitude, a measure of conditioned fear, in response to foot shock.3
WARNING This product is not for human or veterinary use.
1. Angiotensin (5-
2. Inhibition of renin release from rat kidney slices by the angiotensins. Am. J. Physiol. 235(1), F62-F68 (1978).
3. Effects of angiotensin (5-